By Fineline Cube 
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study at the 2025 ASCO Annual Meeting. The study evaluated benmelstobart combined with anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) and met its primary endpoint of progression-free survival (PFS).
Study Results
In the TPS ≥50% population, the benmelstobart/anlotinib combo demonstrated a median PFS improvement of 6.1 months compared to the control group, with a 40% reduction in the risk of disease progression or death. In the overall population, the combo achieved a median PFS of 11.0 months versus 7.1 months in the control group, representing a 30% risk reduction.
Efficacy and Safety
The benmelstobart/anlotinib combo delivered a 57.3% objective response rate (ORR) and 85.9% disease control rate (DCR), compared to 39.5% and 79.1% in the pembrolizumab group. The combo showed favorable tolerability with no new safety signals observed.
Clinical Significance
The CAMPASS study is the first global Phase III trial evaluating an anti-PD-L1 monoclonal antibody combined with a multi-target antiangiogenic TKI as first-line therapy for PD-L1-positive advanced NSCLC. The results demonstrate clinically meaningful benefits for patients.-Fineline Info & Tech